Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.09.2014 | short review

Myelodysplastic syndromes (MDS)

verfasst von: Sonja Burgstaller, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases characterized by ineffective haematopoiesis and cytopenias in peripheral blood. Transformation into acute myeloid leukaemia is a common complication of MDS. Life expectancy varies between nearly normal and early death. MDS were an important issue at last year’s annual meeting of the American Society of Hematology. Like in the years before, the majority of contributions dealt with preclinical aspects. In addition to that, several interesting clinical studies regarding diagnosis and treatment were presented.
Vorheriger Artikel Aggressive lymphoma at ASH 2013: R-CHOP under attack?
Nächster Artikel ASH 2013: short review on myeloproliferative neoplasms
Literatur
1.
Bennet JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–99.CrossRef
2.
Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88.PubMed
3.
Greenberg P, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.PubMedCrossRef
4.
Font P, Loscertales J, Soto C, et al. Inter-observer discordance with the diagnosis of myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and repurducibility of the threshold of 2 % blasts. Blood. 2013;122:abstract 2768.
5.
Nagata Y, Grossmann V, Okuno Y, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Blood. 2013;122:abstract 521.
6.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher risk myelodysplastic syndromes: a randomised, open-label phase III study. Lancet Oncol. 2009;10:223–32.PubMedCrossRefPubMedCentral
7.
Prébet T, Gore DS, Esterni B, Gardin C, Itzykson R, Thepot S, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29:475–83.CrossRef
8.
Ades L, Guerci-Bresler A, Makhoul PC, et al. A phase II study of the efficacy and safety of an intensified schedule of azacitidine (AZA) in intermediate-2 and high risk MDS patients. Blood. 2013:abstract 1513.
9.
Garcia-Manero G, Savona M, Gore SD, et al. Hematologic response to oral azacitidine (CC-486) in subjects with WHO-defined RAEB-1 or RAEB-2 myelodysplastic syndromes (MDS). Blood. 2013;122:abstract 1554.
10.
Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110:4385–95.PubMedCrossRef
11.
Fenaux P, Giagounidis A, Sellelag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118:3765–76.PubMedCrossRef
12.
List A, Dewald G, Bennet J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:456–65.CrossRef
13.
Komrokji RS, Al Ali MH, Pandron E, et al. A phase II clinical trial of lenalidomide and prednisone in low and intermediate-1 risk, non-del(5q) MDS patients. Blood. 2013;122:abstract 1506.
14.
Raza A, Tycko B, Lee S, et al. Oral rigosertib (ON01910.Na) treatment produces an encouraging rate of transfusion independence in lower risk myelodysplastic syndromes (MDS) patients; a genomic methylation profile is associated with responses. Blood. 2013;122:abstract 2745.
15.
Valent P, Krieger O, Stauder R, et al. Iron overload in myelodysplastic syndrmes (MDS) – diagnosis, management, and response criteria: a proposal of the Austrian MDS platform. Eur J Clin Invest. 2008;38:143–9.PubMedCrossRefPubMedCentral
16.
Lyons RM, Marek BJ, Paley CS, et al. 48-month update on survival and AML transformation in a 600-patient registry of lower risk MDS patients. Blood. 2013;122:abstract 2775.
17.
Michallet M, Sobh M, Morisset S, et al. Significant impact of iron chelation after allogeneic hematopoietic stem cell transplantation on disease recurrence: potential of anti-leukemic activity. Blood. 2013;122:abstract 180.
18.
Kantarjian HM, Mufti GJ, Fenaux P, et al. Treatment with romiplostim, a thrombopoietin-receptor agonist, in thrombocytopenic patients with low or intermediate-1 risk myelodysplastic syndrome: updated follow-up results for acute myeloid leukemia and survival from a randomized, double-blind, placebo-controlled study. Blood. 2013;122:abstract 1553.
19.
Prica A, Sholzberg M, Buckstein R. Thrombopoietin (TPO)-receptor agonists in myelodysplastic syndromes (MDS): a systematic review and meta-analysis. Blood. 2013;122:abstract 2806.
20.
Garcia-Manero G, Sekeres MA, List AF, et al. Phase 1 dose-escalation/expansion study of ARRY-614 in patients with IPSS low/int-1 risk myelodysplatic syndromes. Blood. 2013;122:abstract 387.
21.
Garcia-Manero G, Luger SM, Golderg S, et al. A randomized phase II study of sapacitabine in MDS refractory to hypomethylating agents. Blood. 2013;122:abstract 2752.
22.
Silverman LR, Verma A, Odchimar-Reissig R, et al. A phase II trial of epigenetic modulators vorinostat in combination with azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS): initial results of study 6898 of the New York Cancer Consortium. Blood. 2013;122:abstract 386.
Metadaten
Titel
Myelodysplastic syndromes (MDS)
verfasst von
Sonja Burgstaller, MD
Publikationsdatum
01.09.2014
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0158-4

Weitere Artikel der Ausgabe 3/2014

Highlights of the American Society of Hematology Meeting 2013: hemostaseology

  • short review

Aggressive lymphoma at ASH 2013: R-CHOP under attack?

  • short review

ASH 2013: constant progress: not only for B-cell neoplasms

  • editorial

Importance of intraoperative radiation therapy in the treatment of soft tissue sarcoma: data at hand

  • review

Colorectal cancer: screening and some notes on the prevention

  • short review

The challenge of soft tissue sarcomas—critical aspects of therapies with curative intent

  • editorial